Pharmacoeconomical estimate of medical therapy of rheumatoid arthritis with use of monoclonal antibodies to b-lymphocytes (ritycsimab)
With the purpose to estimate pharmacoeconomic effi cacy of use of innovative methods of the therapy of rheumatoid arthritis the use of monoclonal antibodies to -lymphocytes (ritucsimab) and traditional basic antiinfl ammatory preparations has been studied. It has been established that index of cost of disease in the group of patients taking ritucsimab (n=23) amounted to 18301485,26, but in the group, taking traditional therapy (n=150) - 1676644,6 rubls. At the same time it was established that on the background of taking ritucsimab more higher level of life quality, decrease of signifi cance of indexes DAS28, ВАШ, HAQ and ESR were noted. Th e results of investigation conducted allowed to develop organizational methodical approach, proving expedience of use of preparation ritucsimab in pharmacotherapy of rheumatoid arthritis.